Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Evolving treatment paradigms for lipid management over 50 years.
• Increasing focus on aggressive low-density lipoprotein cholesterol (LDL-C) reduction in high-risk patients.
• Prevalence of atherosclerotic cardiovascular disease (ASCVD) necessitates advanced lipid-lowering strategies.

Purpose of the Study:

• To review historical trends in lipid management and therapeutic interventions.
• To examine the current evidence supporting lower LDL-C targets in clinical guidelines.
• To discuss the role of novel non-statin therapies in managing residual ASCVD risk.

Main Methods:

• Comprehensive literature review of cardiovascular outcome trials.
• Analysis of clinical guidelines and recommendations for lipid targets.
• Evaluation of the efficacy of statin and non-statin therapies.

Main Results:

• Statin therapy, particularly high-intensity, demonstrates significant efficacy in reducing ASCVD outcomes.
• Non-statin therapies (ezetimibe, PCSK9 inhibitors, bempedoic acid) further reduce ASCVD risk.
• Emerging evidence supports more stringent LDL-C targets to manage residual risk.

Conclusions:

• Current evidence supports an aggressive approach to LDL-C reduction.
• Novel therapeutic options enable clinicians to achieve lower LDL-C targets.
• Guidelines increasingly reflect the need for intensified lipid management in high-risk populations.